[{"address1": "100 Campus Drive", "city": "Florham Park", "state": "NJ", "zip": "07932", "country": "United States", "phone": "608 441 8120", "website": "https://www.cellectar.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.", "fullTimeEmployees": 20, "maxAge": 86400, "priceHint": 4, "previousClose": 2.8, "open": 2.89, "dayLow": 2.82, "dayHigh": 2.915, "regularMarketPreviousClose": 2.8, "regularMarketOpen": 2.89, "regularMarketDayLow": 2.82, "regularMarketDayHigh": 2.915, "beta": 1.004, "forwardPE": -1.0106007, "volume": 405652, "regularMarketVolume": 405652, "averageVolume": 702664, "averageVolume10days": 533590, "averageDailyVolume10Day": 533590, "bid": 2.85, "ask": 2.88, "bidSize": 200, "askSize": 200, "marketCap": 102527848, "fiftyTwoWeekLow": 1.56, "fiftyTwoWeekHigh": 4.45, "fiftyDayAverage": 3.1568, "twoHundredDayAverage": 3.03095, "currency": "USD", "enterpriseValue": 80123392, "floatShares": 26711392, "sharesOutstanding": 35848900, "sharesShort": 2271661, "sharesShortPriorMonth": 2194327, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0634, "heldPercentInsiders": 0.03202, "heldPercentInstitutions": 0.25558, "shortRatio": 2.9, "shortPercentOfFloat": 0.0719, "impliedSharesOutstanding": 35848900, "bookValue": 0.274, "priceToBook": 10.437956, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -50983864, "trailingEps": -3.09, "forwardEps": -2.83, "lastSplitFactor": "1:10", "lastSplitDate": 1658448000, "enterpriseToEbitda": -1.907, "52WeekChange": 0.5052632, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CLRB", "underlyingSymbol": "CLRB", "shortName": "Cellectar Biosciences, Inc.", "longName": "Cellectar Biosciences, Inc.", "firstTradeDateEpochUtc": 1131633000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d92a6d57-8c29-3e38-89dc-584b57cac7f0", "messageBoardId": "finmb_37613299", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.86, "targetHighPrice": 25.0, "targetLowPrice": 4.0, "targetMeanPrice": 12.6, "targetMedianPrice": 12.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 40031180, "totalCashPerShare": 1.117, "ebitda": -42018520, "totalDebt": 548343, "quickRatio": 2.461, "currentRatio": 2.543, "debtToEquity": 2.096, "returnOnAssets": -0.91470003, "returnOnEquity": -3.04376, "freeCashflow": -15485470, "operatingCashflow": -38554944, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]